Lantern Pharma (LTRN) announced that the European Patent Office has issued a notice of allowance for a composition of matter patent covering its drug candidate LP-284. This patent is expected to be granted in the coming months with exclusivity through early 2039.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LTRN: